Study Watch vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Study Watch

by Verily Life Sciences

EchoNext

by Pathway Labs

AI Verdict

While both tools operate in the Cardiology AI space and are FDA-cleared, they serve different primary functions. Study Watch is a wearable for continuous physiological monitoring in clinical research, collecting raw data for analysis. EchoNext, conversely, is a diagnostic AI tool that analyzes standard ECGs to detect hidden structural heart disease, making it more focused on clinical decision support for existing ECG data.

Choose Study Watch if…

Choose Verily Study Watch if your primary need is continuous, long-term physiological data collection for clinical research, especially for conditions like atrial fibrillation, heart failure progression, or Parkinson's disease. This prescription-only wearable excels at unobtrusive biosensing in real-world settings, providing rich and complex datasets for analysis in Verily's cloud platform.

View Study Watch →

Choose EchoNext if…

Choose EchoNext if you need an AI-powered tool to rapidly screen standard 12-lead ECGs for hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, within a clinical setting. This FDA-cleared solution is designed for broad access, from major hospitals to community practices, and can help identify patients who require further diagnostic imaging like echocardiograms.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Study Watch	EchoNext
Pricing	Not publicly available (device for clinical research and partnerships)	Starts at $600/month
Deployment	Cloud (data uploaded from device to Verily's cloud platform).	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Verily Study Watch is designed for continuous, unobtrusive monitoring in clinical research, with a long battery life and internal data storage, suggesting ease of use for participants. EchoNext, on the other hand, integrates with the OpenEvidence platform, which is used by many physicians, potentially streamlining workflow for clinicians. Without direct user experience comparisons, it's difficult to definitively pick a winner, as both offer different aspects of usability for their respective users.

Clinical Value

EchoNext

EchoNext has demonstrated superior performance in detecting structural heart disease from standard ECGs, even outperforming cardiologists in some studies. It has also been credited with flagging previously undiagnosed heart failure that led to a heart transplant, showcasing a direct impact on patient outcomes. While Verily Study Watch is valuable for continuous physiological monitoring in research, EchoNext's proven diagnostic accuracy and direct clinical impact give it an edge in immediate clinical value.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with discounts for annual plans and add-ons for premium features. Furthermore, it is available free to clinicians through the OpenEvidence platform, making it highly accessible. Verily Study Watch's pricing is not publicly available and is geared towards clinical research and partnerships, making its value proposition less clear for broader clinical adoption. Therefore, EchoNext provides more transparent and potentially broader value.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by over half a million U.S. physicians and has integrations with major hospital systems. This wide deployment and integration capability suggest strong enterprise readiness. Verily Study Watch, while used in large-scale clinical research, is primarily a device for data collection in studies and partnerships, rather than a broadly integrated clinical tool.

Innovation

EchoNext

EchoNext is the first FDA-cleared AI tool to detect six types of structural heart disease using only a standard 12-lead ECG, offering a novel approach to early detection that can even surpass cardiologists' accuracy. This represents a significant innovation in non-invasive cardiac diagnostics. While Verily Study Watch offers continuous physiological monitoring with multiple sensors, its innovation is more in the realm of advanced data collection for research rather than a groundbreaking diagnostic capability for routine clinical use.

Support & Docs

Tie

Neither product's provided information or web search results offer extensive details on specific support channels, documentation availability, or community resources for end-users. Verily's focus on research and partnerships suggests support would be tailored to those collaborations, while EchoNext's deployment through OpenEvidence implies support might be channeled through that platform. Without more specific information for either, it's not possible to declare a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Study Watch	EchoNext
Name	Study Watch	EchoNext
Company	Verily Life Sciences	Pathway Labs
Description	Prescription-only, sensor-based wearable device for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Categories	Cardiology AI, Wearables & Remote Monitoring (RPM)	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Neurology, Sleep Medicine	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine
Key Features	Continuous physiological monitoring, Multiple physiological sensors (ECG, heart rate, electrodermal activity, inertial movements), Long battery life (up to one week), Internal data storage and encryption, Cloud-based data processing with algorithms and machine learning, On-demand single-channel ECG, Irregular pulse monitor, E-ink display for minimal power consumption	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support

Videos

Demos, reviews, and walkthroughs featuring Study Watch and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

EchoNext is designed to integrate into routine workflows through the OpenEvidence clinical decision support platform, which is used by many U.S. clinicians, aiming to embed screening outputs directly into tools physicians already use. This approach avoids requiring a separate workflow or system. Verily Study Watch, on the other hand, is a prescription-only device for continuous physiological monitoring in clinical research, with data collected and analyzed in Verily's cloud platform. Verily is exploring how to integrate mobile health data from devices like the Study Watch into clinical care environments and EHRs to support physician-patient relationships.

What is the accuracy and sensitivity of each tool in detecting relevant conditions?

EchoNext has demonstrated high accuracy in detecting structural heart disease (SHD), with an area under the receiver operating characteristic curve (AUROC) of 85.2% in internal tests and 78-80% in external validation. In studies, EchoNext achieved 77% accuracy in identifying structural heart problems from ECGs, outperforming cardiologists who had 64% accuracy without AI assistance and 69% with AI assistance. The Verily Study Watch has shown a sensitivity of 0.97 and specificity of 0.70 in classifying sleep versus wake, and an accuracy of 0.78 for classifying all four sleep stages. It has also been used in studies to detect irregular pulse and to investigate the association of digital walking measures with heart failure progression.

What is the learning curve for physicians and what kind of support is available for each tool?

EchoNext is integrated into the OpenEvidence platform, which is already used by many clinicians, suggesting a potentially lower learning curve as it leverages existing physician familiarity with that platform. The integration aims to provide screening outputs directly within tools physicians already use. For the Verily Study Watch, while it is designed for unobtrusive biosensing and ease of use for participants, specific details on physician learning curve and support quality beyond its use in clinical research settings are not explicitly detailed. However, Verily emphasizes its collaborative team of clinical and data scientists, engineers, and regulatory experts in pursuing its vision.

How quickly can a practice expect to see value from implementing these tools?

EchoNext aims to provide rapid value by enabling earlier detection of structural heart disease from routine ECGs, potentially leading to more timely interventions and improved allocation of imaging resources. Its integration into OpenEvidence is intended to make this breakthrough available quickly across various care settings. The Verily Study Watch is primarily used in clinical research to collect continuous physiological data, which contributes to understanding disease progression and informing future clinical care. The value here is more focused on accelerating research and generating evidence for precision health solutions over time.

Are there customer references or case studies available to demonstrate real-world impact?

EchoNext has several compelling real-world examples, including a peer-reviewed case where it detected undiagnosed heart failure in a patient who ultimately received a heart transplant. Other cases include detection of severe aortic stenosis leading to a TAVR procedure and severe mitral regurgitation leading to mitral valve annuloplasty. The Verily Study Watch has been deployed in numerous clinical research studies, including the Personalized Parkinson's Project and the Project Baseline Health Study, with publications demonstrating its ability to capture sleep measures and walking activity in diverse populations.

What clinical context should a physician consider when choosing between these two tools, particularly for multi-site rollouts?

The choice depends on the clinical objective: Verily Study Watch is a prescription-only wearable for continuous physiological monitoring in clinical research, suitable for generating rich, longitudinal datasets across diverse populations in studies, including multi-site deployments. EchoNext is an AI tool for analyzing standard ECGs to detect hidden structural heart disease, designed for broad access and integration into existing clinical decision support platforms like OpenEvidence, making it suitable for widespread screening in various care settings, from major hospitals to community practices. For multi-site rollouts, EchoNext's integration with a widely used platform suggests a more streamlined deployment for diagnostic support, while Study Watch's utility is primarily for large-scale data collection in research.